HUMA / FDUSD

HUMA / USDC

HUMA / USDT

HUMA / TRY

HUMA / BNB

FLM / USDT

SYRUP / USDC

CFX / USDT

CFX / USDC

SYRUP / USDT

MASK / TRY

MASK / USDT

STX / BTC

RVN / TRY

STX / BNB

RVN / USDT

LPT / BTC

LPT / BNB

STX / TRY

STX / FDUSD

ART NIRMAN LIMITED

HYBRID FINANCIAL SERVICE

THE GROB TEA COMPANY LTD

KREBS BIOCHEMICALS & IND

TVS ELECTRONICS LTD

WEALTH FRST PORT. MG. LTD

CREATIVE EYE LIMITED

MIC ELECTRONICS LTD

HUBTOWN LIMITED

INDEF MANUFACTURING LTD

KHADIM INDIA LIMITED

PRIVI SPECIALITY CHE LTD

NATURAL CAPSULES LIMITED

KALANA ISPAT LIMITED

RACHANA INFRA LTD

HITACHI ENERGY INDIA LTD

REGENCYCERAMICS-LTD

PARAMOUNT SPECIALI FORG L

SIGNPOST INDIA LIMITED

RADIOWALLA NETWORK LTD

Click here to get full coverage on Suven Life Sciences Faces Significant Decline Amid Broader Small-Cap Market Gains - MarketsMojo

Suven Life Sciences Faces Significant Decline Amid Broader Small-Cap Market Gains  MarketsMojo

Suven Life Sciences Faces Significant Decline Amid Broader Small-Cap Market Gains - MarketsMojo

Click here to get full coverage on Venkat Jasti’s billion-dollar gamble: Can Suven Life crack the CNS drug puzzle? - Moneycontrol

Venkat Jasti’s billion-dollar gamble: Can Suven Life crack the CNS drug puzzle?  Moneycontrol

Venkat Jasti’s billion-dollar gamble: Can Suven Life crack the CNS drug puzzle? - Moneycontrol

Click here to get full coverage on Suven-Cohance merger done - Speciality Chemicals Magazine

Suven-Cohance merger done  Speciality Chemicals Magazine

Suven-Cohance merger done - Speciality Chemicals Magazine

Click here to get full coverage on Suven doses first subjects in trial of SUVN-I6107 for cognitive disorders - Clinical Trials Arena

Suven doses first subjects in trial of SUVN-I6107 for cognitive disorders  Clinical Trials Arena

Suven doses first subjects in trial of SUVN-I6107 for cognitive disorders - Clinical Trials Arena

Click here to get full coverage on Suven Life Sciences Share Price Today Down 7% - Equitymaster

Suven Life Sciences Share Price Today Down 7%  Equitymaster

Suven Life Sciences Share Price Today Down 7% - Equitymaster

Click here to get full coverage on Suven Life Sciences divulges new muscarinic M4 receptor PAMs - BioWorld MedTech

Suven Life Sciences divulges new muscarinic M4 receptor PAMs  BioWorld MedTech

Suven Life Sciences divulges new muscarinic M4 receptor PAMs - BioWorld MedTech

Click here to get full coverage on Suven Pharmaceuticals is now Cohance Lifesciences - Indian Pharma Post

Suven Pharmaceuticals is now Cohance Lifesciences  Indian Pharma Post

Suven Pharmaceuticals is now Cohance Lifesciences - Indian Pharma Post

Click here to get full coverage on Suven Pharmaceuticals Acquires Controlling Stake in NJ Bio to Expand ADC Market Reach - Precedence Research

Suven Pharmaceuticals Acquires Controlling Stake in NJ Bio to Expand ADC Market Reach  Precedence Research

Suven Pharmaceuticals Acquires Controlling Stake in NJ Bio to Expand ADC Market Reach - Precedence Research

Click here to get full coverage on Suven Pharma to acquire 56 pc stake in US-based firm for USD 64.4 mn - The Economic Times

Suven Pharma to acquire 56 pc stake in US-based firm for USD 64.4 mn  The Economic Times

Suven Pharma to acquire 56 pc stake in US-based firm for USD 64.4 mn - The Economic Times

Click here to get full coverage on Advent-owned Suven Pharma to buy majority stake in NJ Bio for $64 mn - VCCircle

Advent-owned Suven Pharma to buy majority stake in NJ Bio for $64 mn  VCCircle

Advent-owned Suven Pharma to buy majority stake in NJ Bio for $64 mn - VCCircle

Click here to get full coverage on Suven Pharmaceuticals acquires controlling stake in US-based NJ Bio - CNBC TV18

Suven Pharmaceuticals acquires controlling stake in US-based NJ Bio  CNBC TV18

Suven Pharmaceuticals acquires controlling stake in US-based NJ Bio - CNBC TV18

Click here to get full coverage on Suven Pharma to acquire majority stake in US-based NJ Bio - Business Standard

Suven Pharma to acquire majority stake in US-based NJ Bio  Business Standard

Suven Pharma to acquire majority stake in US-based NJ Bio - Business Standard

Click here to get full coverage on In preparation of Phase II studies, Right Brain Bio signs Manufacturing Agreement with Suven Pharmaceuticals for RB-190 to Target the Root Cause of Parkinson's Disease - PR Newswire

In preparation of Phase II studies, Right Brain Bio signs Manufacturing Agreement with Suven Pharmaceuticals for RB-190 to Target the Root Cause of Parkinson's Disease  PR Newswire

In preparation of Phase II studies, Right Brain Bio signs Manufacturing Agreement with Suven Pharmaceuticals for RB-190 to Target the Root Cause of Parkinson's Disease - PR Newswire

Click here to get full coverage on Suven Pharma acquires 56% stake in US-based NJ Bio - Times of India

Suven Pharma acquires 56% stake in US-based NJ Bio  Times of India

Suven Pharma acquires 56% stake in US-based NJ Bio - Times of India

Click here to get full coverage on Suven Pharma Eyes $1-Billion Revenue By 2030, Driven By CDMO Expansion - NDTV Profit

Suven Pharma Eyes $1-Billion Revenue By 2030, Driven By CDMO Expansion  NDTV Profit

Suven Pharma Eyes $1-Billion Revenue By 2030, Driven By CDMO Expansion - NDTV Profit

Click here to get full coverage on Why Suven Life Sciences Share Price is Rising - Equitymaster

Why Suven Life Sciences Share Price is Rising  Equitymaster

Why Suven Life Sciences Share Price is Rising - Equitymaster

Click here to get full coverage on Suven Pharma acquires majority stake in US-based NJ Bio - Moneycontrol

Suven Pharma acquires majority stake in US-based NJ Bio  Moneycontrol

Suven Pharma acquires majority stake in US-based NJ Bio - Moneycontrol

Click here to get full coverage on Suven Pharma sets sights on M&As to scale up tech expertise & order book - The Economic Times

Suven Pharma sets sights on M&As to scale up tech expertise & order book  The Economic Times

Suven Pharma sets sights on M&As to scale up tech expertise & order book - The Economic Times

Click here to get full coverage on Sunil Singhania, Prashant Jain invest in Suven Life preferential issue; stock jumps 12% - CNBC TV18

Sunil Singhania, Prashant Jain invest in Suven Life preferential issue; stock jumps 12%  CNBC TV18

Sunil Singhania, Prashant Jain invest in Suven Life preferential issue; stock jumps 12% - CNBC TV18

Click here to get full coverage on 'Sense of urgency' among pharma giants to move beyond China: Suven Pharma Chairman - Moneycontrol

'Sense of urgency' among pharma giants to move beyond China: Suven Pharma Chairman  Moneycontrol

'Sense of urgency' among pharma giants to move beyond China: Suven Pharma Chairman - Moneycontrol

Click here to get full coverage on Suven Pharma to acquire 56% stake in U.S. firm NJ Bio for $64.4 million - The Hindu

Suven Pharma to acquire 56% stake in U.S. firm NJ Bio for $64.4 million  The Hindu

Suven Pharma to acquire 56% stake in U.S. firm NJ Bio for $64.4 million - The Hindu

Click here to get full coverage on Suven to acquire 56% stake in ADC specialist NJ Bio for US$64.4 million - Indian Pharma Post

Suven to acquire 56% stake in ADC specialist NJ Bio for US$64.4 million  Indian Pharma Post

Suven to acquire 56% stake in ADC specialist NJ Bio for US$64.4 million - Indian Pharma Post

Click here to get full coverage on Suven Life Sciences Reaches All-Time High Amid Strong Market Performance - MarketsMojo

Suven Life Sciences Reaches All-Time High Amid Strong Market Performance  MarketsMojo

Suven Life Sciences Reaches All-Time High Amid Strong Market Performance - MarketsMojo

Click here to get full coverage on Macquarie bullish on Suven Pharma, Divi's Labs, Bluejet and Syngene - The Economic Times

Macquarie bullish on Suven Pharma, Divi's Labs, Bluejet and Syngene  The Economic Times

Macquarie bullish on Suven Pharma, Divi's Labs, Bluejet and Syngene - The Economic Times

Click here to get full coverage on Suven Pharmaceuticals Receives NSE Caution Over Disclosure Delay - TipRanks

Suven Pharmaceuticals Receives NSE Caution Over Disclosure Delay  TipRanks

Suven Pharmaceuticals Receives NSE Caution Over Disclosure Delay - TipRanks

Click here to get full coverage on Suven Life Sciences Achieves 52-Week High Amid Broader Market Downturn - MarketsMojo

Suven Life Sciences Achieves 52-Week High Amid Broader Market Downturn  MarketsMojo

Suven Life Sciences Achieves 52-Week High Amid Broader Market Downturn - MarketsMojo

Click here to get full coverage on Goldman Sachs initiates coverage on Suven Pharma and Piramal Pharma - Moneycontrol

Goldman Sachs initiates coverage on Suven Pharma and Piramal Pharma  Moneycontrol

Goldman Sachs initiates coverage on Suven Pharma and Piramal Pharma - Moneycontrol

Click here to get full coverage on Suven Pharmaceuticals Addresses Delay in Auditor Appointment Disclosure - TipRanks

Suven Pharmaceuticals Addresses Delay in Auditor Appointment Disclosure  TipRanks

Suven Pharmaceuticals Addresses Delay in Auditor Appointment Disclosure - TipRanks

Click here to get full coverage on Suven Pharmaceuticals Faces Short-Term Decline Amid Long-Term Growth Resilience - MarketsMojo

Suven Pharmaceuticals Faces Short-Term Decline Amid Long-Term Growth Resilience  MarketsMojo

Suven Pharmaceuticals Faces Short-Term Decline Amid Long-Term Growth Resilience - MarketsMojo

Click here to get full coverage on Suven Life Sciences Achieves New Milestone Amid Strong Market Sentiment in Healthcare Sector - MarketsMojo

Suven Life Sciences Achieves New Milestone Amid Strong Market Sentiment in Healthcare Sector  MarketsMojo

Suven Life Sciences Achieves New Milestone Amid Strong Market Sentiment in Healthcare Sector - MarketsMojo

Click here to get full coverage on Suven Pharmaceuticals Faces Market Sentiment Shift Amid Profit Decline Concerns - MarketsMojo

Suven Pharmaceuticals Faces Market Sentiment Shift Amid Profit Decline Concerns  MarketsMojo

Suven Pharmaceuticals Faces Market Sentiment Shift Amid Profit Decline Concerns - MarketsMojo

Click here to get full coverage on Suven Life Sciences Achieves New High Amid Broader Market Decline - MarketsMojo

Suven Life Sciences Achieves New High Amid Broader Market Decline  MarketsMojo

Suven Life Sciences Achieves New High Amid Broader Market Decline - MarketsMojo

Click here to get full coverage on Suven Life Sciences to present positive results from Phase-2a Proof-of-Concept Study of Ropanicant - Indian Pharma Post

Suven Life Sciences to present positive results from Phase-2a Proof-of-Concept Study of Ropanicant  Indian Pharma Post

Suven Life Sciences to present positive results from Phase-2a Proof-of-Concept Study of Ropanicant - Indian Pharma Post

Click here to get full coverage on Suven Pharma, Divis, Syngene: Why Macquarie is betting big on Indian pharma - Business Standard

Suven Pharma, Divis, Syngene: Why Macquarie is betting big on Indian pharma  Business Standard

Suven Pharma, Divis, Syngene: Why Macquarie is betting big on Indian pharma - Business Standard

Click here to get full coverage on Suven Life Sciences Reports Financial Challenges Amid Declining Performance Metrics in March 2025 - MarketsMojo

Suven Life Sciences Reports Financial Challenges Amid Declining Performance Metrics in March 2025  MarketsMojo

Suven Life Sciences Reports Financial Challenges Amid Declining Performance Metrics in March 2025 - MarketsMojo

Click here to get full coverage on Smallcap stock surges 15%, hits record high today; what's behind the rally? - Business Standard

Smallcap stock surges 15%, hits record high today; what's behind the rally?  Business Standard

Smallcap stock surges 15%, hits record high today; what's behind the rally? - Business Standard

Click here to get full coverage on Rising Bags Private Equity Investment As Parent Suven Pharma Sells Stake - insights.citeline.com

Rising Bags Private Equity Investment As Parent Suven Pharma Sells Stake  insights.citeline.com

Rising Bags Private Equity Investment As Parent Suven Pharma Sells Stake - insights.citeline.com

Click here to get full coverage on Suven Life shares rise 11% on progress in clinical trial of cognitive disorder drug - Moneycontrol

Suven Life shares rise 11% on progress in clinical trial of cognitive disorder drug  Moneycontrol

Suven Life shares rise 11% on progress in clinical trial of cognitive disorder drug - Moneycontrol

Click here to get full coverage on Hyderabad-based drug manufacturer Suven to acquire majority stake in NJ Bio for $64 million - The New Indian Express

Hyderabad-based drug manufacturer Suven to acquire majority stake in NJ Bio for $64 million  The New Indian Express

Hyderabad-based drug manufacturer Suven to acquire majority stake in NJ Bio for $64 million - The New Indian Express

Click here to get full coverage on Suven to Divi’s: Indian CDMOs seize opportunity in pivot away from China amid global trade tensions - Moneycontrol

Suven to Divi’s: Indian CDMOs seize opportunity in pivot away from China amid global trade tensions  Moneycontrol

Suven to Divi’s: Indian CDMOs seize opportunity in pivot away from China amid global trade tensions - Moneycontrol

Click here to get full coverage on Suven Pharma shares in focus after Q3 profit jumps 78% YoY, revenue up 40% - The Economic Times

Suven Pharma shares in focus after Q3 profit jumps 78% YoY, revenue up 40%  The Economic Times

Suven Pharma shares in focus after Q3 profit jumps 78% YoY, revenue up 40% - The Economic Times

Click here to get full coverage on Suven Life Sciences announces positive topline results from Phase-2 PoC signal detection open label study of Ropanicant - Indian Pharma Post

Suven Life Sciences announces positive topline results from Phase-2 PoC signal detection open label study of Ropanicant  Indian Pharma Post

Suven Life Sciences announces positive topline results from Phase-2 PoC signal detection open label study of Ropanicant - Indian Pharma Post

Click here to get full coverage on Suven Life spurts on initiating Phase-1 of clinical trial in US - Business Standard

Suven Life spurts on initiating Phase-1 of clinical trial in US  Business Standard

Suven Life spurts on initiating Phase-1 of clinical trial in US - Business Standard

Click here to get full coverage on Suven Life Sciences Q4 Net Loss Widens Over 65% As Revenue Falls 39% - Free Press Journal

Suven Life Sciences Q4 Net Loss Widens Over 65% As Revenue Falls 39%  Free Press Journal

Suven Life Sciences Q4 Net Loss Widens Over 65% As Revenue Falls 39% - Free Press Journal

Click here to get full coverage on Suven Pharma appoints Declan Ryan as CCO - Indian Pharma Post

Suven Pharma appoints Declan Ryan as CCO  Indian Pharma Post

Suven Pharma appoints Declan Ryan as CCO - Indian Pharma Post

Click here to get full coverage on NCLT approves amalgamation of Suven Pharma, Cohance Lifesciences - Business Standard

NCLT approves amalgamation of Suven Pharma, Cohance Lifesciences  Business Standard

NCLT approves amalgamation of Suven Pharma, Cohance Lifesciences - Business Standard

Click here to get full coverage on Goldman Sachs sees up to 28% upside in two 'consensus buy' pharma stocks - CNBC TV18

Goldman Sachs sees up to 28% upside in two 'consensus buy' pharma stocks  CNBC TV18

Goldman Sachs sees up to 28% upside in two 'consensus buy' pharma stocks - CNBC TV18

Click here to get full coverage on Its official: Suven Pharma and Cohance Lifesciences merger to take effect from May 1 - financialexpress.com

Its official: Suven Pharma and Cohance Lifesciences merger to take effect from May 1  financialexpress.com

Its official: Suven Pharma and Cohance Lifesciences merger to take effect from May 1 - financialexpress.com

Click here to get full coverage on Advent-controlled Suven Pharma appoints former Piramal exec as chairman - VCCircle

Advent-controlled Suven Pharma appoints former Piramal exec as chairman  VCCircle

Advent-controlled Suven Pharma appoints former Piramal exec as chairman - VCCircle

Click here to get full coverage on Suven Pharmaceuticals renamed as Cohance Lifesciences - Business Standard

Suven Pharmaceuticals renamed as Cohance Lifesciences  Business Standard

Suven Pharmaceuticals renamed as Cohance Lifesciences - Business Standard

Click here to get full coverage on Suven Life Sciences shares ended 10% higher after this important announcement - CNBC TV18

Suven Life Sciences shares ended 10% higher after this important announcement  CNBC TV18

Suven Life Sciences shares ended 10% higher after this important announcement - CNBC TV18

Click here to get full coverage on NCLT sanctions amalgamation of Cohance Lifesciences into Suven Pharmaceuticals - Times of India

NCLT sanctions amalgamation of Cohance Lifesciences into Suven Pharmaceuticals  Times of India

NCLT sanctions amalgamation of Cohance Lifesciences into Suven Pharmaceuticals - Times of India

Click here to get full coverage on Suven Life Sciences Share Price Today Up 10% - Equitymaster

Suven Life Sciences Share Price Today Up 10%  Equitymaster

Suven Life Sciences Share Price Today Up 10% - Equitymaster

Click here to get full coverage on Suven Pharmaceuticals rebrands as Cohance Lifesciences - bestmediainfo.com

Suven Pharmaceuticals rebrands as Cohance Lifesciences  bestmediainfo.com

Suven Life Sciences Limited (SUVEN)

Price Chart

Key Statistics

Technicals

About SUVEN

Latest News

Suven Life Sciences Faces Significant Decline Amid Broader Small-Cap Market Gains - MarketsMojo

Venkat Jasti’s billion-dollar gamble: Can Suven Life crack the CNS drug puzzle? - Moneycontrol

Suven-Cohance merger done - Speciality Chemicals Magazine

Advanced Charts

Top Gainers

Top Losers